Patents Assigned to Deltagen, Inc.
  • SLC19A2 amino acid transporter gene disruptions, and compositions and methods related thereto
    Patent number: 7176346
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an SLC19A2 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: June 24, 2003
    Date of Patent: February 13, 2007
    Assignee: Deltagen, Inc.
    Inventor: Robert G. Wisotzkey
  • HSPC150-like gene disruptions, compositions and methods related thereto
    Patent number: 7164055
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a HSPC150-like gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: January 16, 2007
    Assignee: Deltagen, Inc.
    Inventor: Michael W. Leviten
  • CYT28 serpentine receptor disruptions, compositions and methods relating thereto
    Patent number: 7030291
    Abstract: The present invention relates to compositions and methods relating to the characterization and function of CYT28. Specifically, the present invention provides transgenic animals comprising disruptions in a CYT28 gene and methods of treating diseases conditions, such as pain. The present invention further relates to agents that modulate CYT28 and methods of screening for agents that modulate CYT28 for the treatment of diseases and conditions such as pain.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: April 18, 2006
    Assignee: Deltagen, Inc.
    Inventor: Keith D. Allen
  • Secreted protein associated with depression, compositions and methods of use thereof
    Publication number: 20060037094
    Abstract: The present invention relates to compositions and methods relating to the characterization of gene function. More particularly, the present invention relates to the role of secreted protein genes involved in neurobiological disorders, and in particular, depression. In addition, the present invention provides transgenic mice comprising mutations in a secreted protein gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions, including depression.
    Type: Application
    Filed: October 21, 2005
    Publication date: February 16, 2006
    Applicant: Deltagen, Inc.
    Inventors: Russell Phillips, Thadd Reeder, Keith Allen
  • Methods of creating constructs useful for introducing sequences into embryonic stem cells
    Patent number: 6942995
    Abstract: This invention provides novel nucleotide constructs. Also provided are methods for making DNA constructs useful for introducing sequences into and disrupting the function of a gene in a cell, particularly an embryonic stem cell.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: September 13, 2005
    Assignee: Deltagen, Inc.
    Inventors: Robert D. Klein, Thomas J. Brennan
  • Transgenic mice containing stefin homolog protease inhibitor gene disruptions
    Patent number: 6943277
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a stefin homolog gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: September 13, 2005
    Assignee: Deltagen, Inc.
    Inventor: Keith D. Allen
  • Gene targeting vectors comprising conditional positive selection markers
    Patent number: 6929909
    Abstract: The present invention is directed to methods and compositions useful in producing cells and animals having a disruption or modification of a target gene. Vectors useful in producing these cells and animals are described. In addition, methods of screening and enriching cells comprising a targeted gene modification are provided.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: August 16, 2005
    Assignee: Deltagen, Inc.
    Inventors: Christian Siebel, Thomas J. Brennan
  • Transgenic mice containing glucagon receptor gene disruptions
    Patent number: 6909031
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a glucagon receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions. The present invention also relates to diabetes and diabetic condition, as it demonstrates the role of the glucagon receptor in diabetes and diabetic conditions. The present invention further relates to weight gain and weight related conditions, such as obesity, and demonstrates the role of the glucagon receptor in weight gain and weight related conditions, such as obesity.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: June 21, 2005
    Assignee: Deltagen, Inc.
    Inventors: Keith D. Allen, Mark Moore, William Matthews
  • Transgenic mice containing magnesium-dependent protein phosphatase gene disruptions
    Patent number: 6858772
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in the magnesium-dependent protein phosphatase gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: February 22, 2005
    Assignee: Deltagen, Inc.
    Inventor: Keith D. Allen
  • Transgenic mice containing BMP gene disruptions
    Patent number: 6784335
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a BMP gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: August 31, 2004
    Assignee: Deltagen, Inc.
    Inventor: Keith D. Allen
  • Transgenic mice containing NPY6-R neuropeptide receptor gene disruptions
    Patent number: 6765126
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a NPY6 receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: July 20, 2004
    Assignee: Deltagen Inc.
    Inventor: Keith D. Allen
  • Transgenic mice containing intestinal alkaline phosphatase gene disruptions
    Patent number: 6762342
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in an intestinal alkaline phosphatase gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: July 13, 2004
    Assignee: Deltagen, Inc.
    Inventor: Keith D. Allen
  • Transgenic mice containing retina-specific nuclear receptor gene disruptions
    Patent number: 6730821
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in genes, which are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: May 4, 2004
    Assignee: Deltagen, Inc.
    Inventor: Catherine Guenther
  • Transgenic mice containing DEZ orphan receptor gene disruptions
    Patent number: 6717032
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a DEZ receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: April 6, 2004
    Assignee: Deltagen, Inc
    Inventor: Thomas J. Brennan
  • Transgenic mice exhibiting increased susceptibility to seizures
    Patent number: 6653526
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a ubiquitin-specific protease 16 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: November 25, 2003
    Assignee: Deltagen, Inc.
    Inventor: Michael W. Leviten
  • Methods of creating constructs useful for introducing sequences into embryonic stem cells
    Publication number: 20020197624
    Abstract: This invention provides novel nucleotide constructs. Also provided are methods for making DNA constructs useful for introducing sequences into and disrupting the function of a gene in a cell, particularly an embryonic stem cell.
    Type: Application
    Filed: February 28, 2002
    Publication date: December 26, 2002
    Applicant: DELTAGEN, INC.
    Inventors: Robert D. Klein, Thomas J. Brennan
  • Methods of creating constructs useful for introducing sequences into embryonic stem cells
    Publication number: 20020086369
    Abstract: This invention provides novel nucleotide constructs. Also provided are methods for making DNA constructs useful for introducing sequences into and disrupting the function of a gene in a cell, particularly an embryonic stem cell.
    Type: Application
    Filed: June 19, 2001
    Publication date: July 4, 2002
    Applicant: DELTAGEN, INC.
    Inventors: Robert D. Klein, Thomas J. Brennan